Chen Bihua, director, granted 31,675 options at BridgeBio Oncology (BBOT)
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics director and 10% owner Chen Bihua received a grant of stock options for 31,675 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders that follows the grant date, provided Chen continues to serve the company through that vesting date. After this grant, Chen holds 31,675 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Chen Bihua
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 31,675 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 31,675 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 31,675 options
Exercise price: $7.73 per share
Underlying shares: 31,675 shares
+2 more
5 metrics
Options granted
31,675 options
Stock Option (Right to Buy) grant to Chen Bihua
Exercise price
$7.73 per share
Exercise price of granted stock options
Underlying shares
31,675 shares
Common stock underlying the stock options
Expiration date
June 15, 2036
Option expiration date
Post-grant derivative holdings
31,675 derivatives
Total derivative securities held after this grant
Key Terms
Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 7.7300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
vesting financial
"The shares underlying the stock option vest in full upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
ten percent owner regulatory
"is_ten_percent_owner: 1"
FAQ
What did BridgeBio Oncology Therapeutics (BBOT) report in this Form 4?
BridgeBio Oncology Therapeutics reported that director and 10% owner Chen Bihua received a grant of 31,675 stock options. These options relate to the company’s common stock and represent compensation rather than an open-market share purchase or sale.
How many BridgeBio Oncology (BBOT) options were granted to Chen Bihua?
The filing shows a grant of 31,675 stock options to director and 10% owner Chen Bihua. Each option is exercisable into one share of BridgeBio Oncology common stock, subject to vesting and an exercise price specified in the award.
What is the exercise price of Chen Bihua’s BBOT stock options?
The granted stock options have an exercise price of $7.73 per share. This means Chen must pay $7.73 for each share of common stock when exercising the options, once they are vested and before the stated expiration date.
When do Chen Bihua’s BridgeBio Oncology options vest?
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders after the grant. Vesting requires Chen’s continued service with BridgeBio Oncology through the applicable vesting date.
When do the newly granted BBOT stock options expire?
The granted stock options expire on June 15, 2036. If they are not exercised by that expiration date, they lapse. The options can only be exercised after they vest and while Chen continues to satisfy any applicable service conditions.
Is this BBOT Form 4 a stock purchase or a compensation grant?
This Form 4 reflects a compensation-related grant of stock options, not an open-market stock purchase or sale. The options were awarded to director and 10% owner Chen Bihua at a preset exercise price and subject to vesting conditions.